Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.62 |
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | PLAU | P00749 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989502 | 0.88 | ELANE (0.73) | ELANEF2PLAUSCN9A | |
| SCHEMBL27758519 | 0.86 | ELANE (0.57) | ELANEF2PLAUCYP1A2CYP3A4 | |
| SCHEMBL4476722 | 0.81 | ELANE (0.72) | ELANEF2PLAU | |
| SCHEMBL960403 | 0.79 | ELANE (0.44) | ELANEF2PLAUCYP3A4CYP2C9 | |
| SCHEMBL22383016 | 0.79 | ELANE (0.50) | ELANEF2PLAUCYP1A2CYP3A4 | |
| SCHEMBL4258294 | 0.79 | TSHR (0.52) | ELANEF2PLAUCYP1A2CYP3A4 | |
| SCHEMBL2589646 | 0.77 | ELANE (0.59) | ELANEF2PLAU | |
| SCHEMBL14863708 | 0.77 | ELANE (0.47) | ELANEF2PLAUSCN9ARORC | |
| SCHEMBL20674557 | 0.77 | TSHR (0.47) | ELANEF2PLAUCYP1A2CYP3A4 | |
| SCHEMBL27732380 | 0.76 | ELANE (0.72) | ELANEF2PLAURORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106535890-A | 5-substituted indazole-3-carboxamides and preparation and use thereof | 萨穆梅德有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-118203009-A | Application of indazole-3-carboxylic acid in preventing and treating plant bacterial diseases | 中国热带农业科学院环境与植物保护研究所 | 2024-06-18 | — | — | CN | disclosed |
| CN-109705097-A | Indazole -3- carboxylic acid amides and its purposes as WNT/ β-CATENIN signal transduction pathway inhibitor | 萨穆梅德有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109705097-A | Indazole -3- carboxylic acid amides and its purposes as WNT/ β-CATENIN signal transduction pathway inhibitor | 萨穆梅德有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108290879-A | Heteroaryl compound and application thereof as IRAK inhibitor | 默克专利有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-104936950-B | The carboxamide derivative of 1H indoles 3 and its purposes as P2Y12 antagonists | 赛诺菲 | 2017-08-08 | — | — | CN | disclosed |
| CN-106535890-A | 5-substituted indazole-3-carboxamides and preparation and use thereof | 萨穆梅德有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-104936950-A | 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists | SAI NUOFEI | 2015-09-23 | — | — | CN | disclosed |
| CN-103929963-A | Indazole-3-carboxamides and their use as WNT/beta-CATENIN signaling pathway inhibitors | SAMUMED LLC | 2014-07-16 | — | — | CN | disclosed |
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
| US-20060135516-A1 | 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors | ASTEX TECHNOLOGY, LTD. (GB) | 2006-06-22 | — | — | US | disclosed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1546156-A1 | 3-(CARBONYL) 1H-INDAZOLE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004014922-A1 | 3-(CARBONYL) 1H-INDAZOLE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| US-3956312-A | ANTISECRETORY AGENT | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | ELANE 1677/4885F2 2563/4885PLAU 4405/4885 |
| US-20060135516-A1 | 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors | CCNI, CDK3, CDK2 | ELANE 3783/4885F2 1499/4885PLAU 4493/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | ELANE 4267/4885F2 2452/4885PLAU 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.